Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseasesPUBT·19 hours ago06996+2.31%
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&DPR Newswire·1 day ago, 08:00 PM06996+2.31%UCB-0.96%
Antengene FY26 H1 returns to profit at RMB 216.35 million; revenue more than doubled to RMB 513.08 millionPUBT·Aug 21 at 05:27 AM06996+2.31%UCBJY+1.74%
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech SummitPR Newswire·Aug 18 at 08:00 PM06996+2.31%
Antengene files board, board committee member list with disclosure rolesPUBT·Aug 2 at 07:02 PM06996+2.31%
Antengene names Bing Hou executive director as CFO Donald Lung resignsPUBT·Jul 31 at 03:56 AM06996+2.31%
ANTENGENE-B Expects Interim Turn to Profit with Earnings of Up to RMB238MAASTOCKS News·Jul 27 at 08:39 PM06996+2.31%UCBJY+1.74%
Antengene files HKEX next-day disclosure return reporting share repurchase at HKD 4.11 eachPUBT·Jul 21 at 04:35 AM06996+2.31%
Antengene files HKEX next-day return disclosing share repurchase for treasury sharesPUBT·Jul 20 at 04:59 AM06996+2.31%
Antengene announces ESMO 2026 poster presentations for ATG-022, ATG-037PUBT·Jul 20 at 02:02 AM06996+2.31%
Antengene files HKEX next-day disclosure return on share repurchase for treasury shares at HKD 4.45 eachPUBT·Jul 16 at 05:08 AM06996+2.31%
Antengene files HKEX next-day return disclosing share repurchase at HKD 4.31-4.23PUBT·Jul 13 at 06:56 AM06996+2.31%
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCBPR Newswire·Jul 12 at 11:00 PM06996+2.31%UCB-0.96%
